Synopsis:
Welcure Drugs & Pharmaceuticals Limited signed an LOI with Singapore’s Telexcell Trade to acquire up to a 25% stake at ₹20 per share.
This Penny Stock under Rs. 10, engaged in the manufacturing and wholesale of pharmaceutical formulations, tablets, capsules, dry syrups, antibiotics, and botanical products, serves domestic and global markets and hits a 5 percent upper circuit after signing an LOI with Telexcell Trade PTE Limited, Singapore, for a 25 percent stake at Rs. 20 per share.
With a market capitalization of Rs. 108.91 crores, the shares of Welcure Drugs and Pharmaceuticals Limited hit a 5 percent upper circuit of Rs. 9.68 per share on Thursday, up from its previous closing price of Rs. 9.22 per share.
Recent Updates
Welcure Drugs and Pharmaceuticals Limited has signed a Letter of Intent (LOI) with Telexcell Trade PTE Limited, Singapore, for a potential equity investment. Telexcell plans to acquire up to a 25 percent stake at Rs. 20 per share. The investment is subject to due diligence, regulatory approvals, and shareholder permissions, with both sides aiming to complete the process within 90 days.
The company stated that this partnership will help expand its global presence and unlock opportunities in emerging markets. Management highlighted that, along with recent corporate actions such as a stock split and bonus issue, this step reflects confidence in the company’s business model and commitment to creating long-term value for shareholders.
In addition, Welcure earlier announced plans to invest Rs. 70–80 crore in setting up a modern agro-pharma research laboratory that will follow cGMP standards. To support this, the company proposes to raise up to Rs. 80 crore through QIP. The facility will be designed to meet US FDA botanical drug guidelines, enabling entry into international markets for botanical and ayurvedic products after securing necessary approvals.
Bonus Share and Stock Split
On August 22, 2025, the Board of Directors of Welcure Drugs and Pharmaceuticals Limited has announced a stock split in a 10:1 ratio, meaning each Rs. 10 share will be divided into ten shares of Re. 1 each.
Additionally, the company has also approved issuing bonus shares in the ratio of 1:10, meaning shareholders will receive one fully paid-up equity share for every ten fully paid-up equity shares held. The record date will be announced in the future.
Company Overview
Welcure Drugs and Pharmaceuticals Limited was incorporated in 1992 and is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.
Recent quarter results
Coming into financial highlights, Welcure Drugs & Pharmaceuticals Limited’s revenue has increased from Rs. 21.21 crore in Q4 FY25 to Rs. 299.91 crore in Q1 FY26, which has grown by 1,314 percent. The net profit has also grown by 831.6 percent from Rs. 2.50 crore in Q4 FY25 to Rs. 23.29 crore in Q1 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 2.45 percent and 4.18 percent, respectively. Welcure Drugs & Pharmaceuticals Limited has an earnings per share (EPS) of Rs. 0.19, and its debt-to-equity ratio is 1.20x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
